ArticleCurrent medicinal chemistry2026
The Protective Effects of
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFerula assa-foetida L. has traditionally been used to treat various diseases, including infections, asthma, stomach aches, and flatulence. Previous studies have highlighted its anti-inflammatory, anti-oxidative, anti-diabetic, neuroprotective, and nerve-stimulating properties.
objectiveThis study aimed to evaluate the therapeutic effects and molecular mechanisms of action of the oleo-gum resin from Ferula assa-foetida L. in an animal model of diabetic neuropathy (DN).
methodsThe essential oil of oleo-gum resin from Ferula assa-foetida L. was analyzed using Gas Chromatography-Mass Spectrometric Analysis. Forty-two male Wistar rats were included in the study, with diabetes induced via streptozotocin (STZ) injection. The rats were randomly assigned to seven groups (n=6 per group) and treated with different doses of Ferula assa-foetida L. extract (100, 200 mg/kg/day) or oil (10, 20 mg/kg/day), alongside appropriate control groups. After a five-week treatment period, samples of dorsal root ganglia (DRG), pancreatic tissue, and blood were collected. Key parameters assessed included blood glucose and insulin levels, motor function tests, oxidative stress protein generation, pro-inflammatory cytokine gene expression, and histopathological analyses.
resultsTreatment with various doses of Ferula assa-foetida L. extract or oil, as well as gabapentin, led to significant improvements. These included reduced blood sugar levels, increased insulin levels, and improved glycemic control. Motor function was enhanced, while the expression of pro-inflammatory cytokines and oxidative stress markers was significantly reduced.
conclusionThese findings indicate a promising therapeutic approach for managing DN. Further studies are warranted to elucidate the underlying mechanisms of Ferula assa-foetida L.'s beneficial effects in DN.
Indexed as
Identifiers
40108916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.